COVAXX to Present Data on COVID-19 Vaccine Candidate UB-612 at Two Virtual Scientific Conferences

October 20, 2020 7:42 AM EDT | Source: Reportable, Inc.

Hauppauge, New York--(Newsfile Corp. - October 20, 2020) - COVAXX, a U.S. company developing a synthetic multitope peptide-based vaccine to fight COVID-19, today announced that Chief Scientific Officer Dr. Farshad Guirakhoo will present new data on COVAXX's vaccine candidate, UB-612, and participate in panel discussions at the following conferences:

World Vaccine Congress Europe

Session title: “Vaccine Technologies to Tackle COVID-19 Presentations”
Session date: Wednesday, October 21, at 9:10 am EDT

Festival of Biologics: World Immunotherapy Congress

Session title: “UB-612: A multitope peptide-based vaccine entering clinic”
Session date: Monday, November 2, at 10:40 am EST
Session title: “Progress on COVID-19 vaccine development programs”
Session date: Monday, November 2, at 11:40 pm EST

To view the full announcement, including downloadable images, bios, and more, click here.

 

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7294/66395_figure1_550.jpg

Click image above to view full announcement.

About COVAXX.

COVAXX is developing a Multitope Peptide-Based Vaccine for COVID-19. The investigational vaccine has shown promising preclinical safety and efficacy data and is based on a commercially proven, scalable vaccine platform. The mission of COVAXX is to safeguard lives by tackling the global COVID-19 pandemic using cost-effective, scalable and proven science-based solutions delivered to the world.

COVAXX is a subsidiary of United Biomedical Inc (UBI), founded in 1985 and headquartered in New York. UBI has established a long legacy as a scientific trailblazer creating technological firsts, including the manufacture and commercialization of more than 100 million antibody blood diagnostic tests and 5 billion vaccine doses against virulent diseases in animal health. With exclusive access to UBI's core technology platforms, COVAXX can operate worldwide in developing and commercializing high precision antibody tests and developing a COVID-19 vaccine that together would form a unique DIVI system (Differentiating Infected from Vaccinated Individuals) that would be of high demand once vaccination programs are on their way worldwide in the not too distant future.

For more information, visit www.covaxx.com and follow us on social media.

Contacts:

Diane Murphy
(310) 658.8756
diane@covaxx.com

David Schull
(212) 845-4271
David.Schull@russopartnersllc.com

Ignacio Guerrero-Ros
6462496817
ignacio.guerrero-ros@russopartnersllc.com

Source: COVAXX

Distributed by: Reportable, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66395

info